Teleflex Incorporated (NYSE:TFX) Stock Has Consensus Price Target of $155.20 According to Analysts

Teleflex Incorporated (NYSE:TFX) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, five have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $155.20.

TFX has been the subject of a number of research analyst reports. UBS Group increased their target price on shares of Teleflex from $145.00 to $158.00 and gave the company a “neutral” rating in a report on Tuesday, August 11th. Wall Street Zen raised Teleflex from a “sell” rating to a “hold” rating in a research note on Sunday, August 9th. Bank of America raised Teleflex from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $145.00 to $158.00 in a research note on Monday, September 28th. Mizuho lifted their price objective on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st.

Teleflex Stock Performance

Shares of TFX stock opened at $125.86 on Tuesday. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94. The stock has a 50 day simple moving average of $132.07 and a 200-day simple moving average of $129.98. The company has a market cap of $5.33 billion, a price-to-earnings ratio of -5.40, a price-to-earnings-growth ratio of 0.84 and a beta of 0.83. Teleflex has a 12-month low of $100.18 and a 12-month high of $145.00.

Teleflex (NYSE:TFX) last posted its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. Teleflex had a positive return on equity of 11.93% and a negative net margin of 39.67%. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. During the same period in the previous year, the business earned $3.73 earnings per share. The company’s revenue for the quarter was up 28.9% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, equities analysts forecast that Teleflex will post 7.22 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Friday, August 14th were issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date was Friday, August 14th. Teleflex’s dividend payout ratio (DPR) is -5.84%.

Institutional Trading of Teleflex

Several institutional investors and hedge funds have recently modified their holdings of the business. Kelleher Financial Advisors acquired a new position in Teleflex during the 2nd quarter worth approximately $25,000. Allworth Financial LP acquired a new stake in shares of Teleflex during the second quarter valued at about $44,000. Versant Capital Management Inc boosted its stake in shares of Teleflex by 573.4% during the second quarter. Versant Capital Management Inc now owns 431 shares of the medical technology company’s stock valued at $55,000 after purchasing an additional 367 shares in the last quarter. Trust Co. of Vermont bought a new position in Teleflex in the 2nd quarter valued at approximately $57,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Teleflex during the 2nd quarter worth approximately $57,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, physicians and other healthcare providers. Its products are designed to support minimally invasive procedures, critical care and a range of clinical applications.

The company’s portfolio includes devices for vascular access and intervention, anesthesia, respiratory care, emergency medicine, surgery, urology and pain management. Teleflex markets products under brands including Arrow, which is known for vascular access and catheter-based technologies, as well as other specialized product lines used in hospitals and outpatient settings.

Teleflex serves healthcare markets in North America, Europe, Asia and other international regions.